$MREO On RARE’s Q&A: BMD does not yet have the same accepted predictive link to fractures in OI that it has in osteoporosis. “At this point, we’re looking at fracture endpoints of some form as the primary
If BMD is not accepted as a predictive link, why is it a 2ndary endpoint?
$MREO Waiting for this stock is very frustrating. Seems this will drag out till November at least.
Any price estimates if we get preliminarily positive path (such as only OLE extension data, conditional approval, re-analysis of current data) and exercise of upfront Alv paymnt?
$MREO RARE said publicly that they will have an answer on our next steps before their Angelman data which unblinds in Q3/Q4 timeline.
Wait time is not over.
$MREO besides Alvelestat, which we are all waiting for, management needs to provide a clear timeline on at least the following two:
1) Data analysis completion expectation.
2) Requesting a type C meeting with FDA.
Rand Paul was a big boost to Trump when the rest of Congress - especially Republicans - would rather see him in the dock. He stuck his neck out for Trump, asking nothing in return.
He stood by President Trump through the insane impeachment garbage and even with the J6 garbage.
He NEVER turned on Trump even though it would have been politically expedient to do so. Paul could have made big points - and probably raised big money - by piling on Trump when Trump was under attack.
He refused to do so.
And this is how Trump repays such loyal friendship.
I have never seen anything like it in all my years in politics.
--Daniel McAdams, executive director, Ron Paul Institute